ArticleCirculation2026

Pulmonary Arterial Hypertension Risk With BCR-ABL Tyrosine Kinase Inhibitors: Refining Risk With Nationwide Data.

Jonah D Garry et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.